JPMorgan Chase & Co. set a €95.00 ($113.10) target price on Merck KGaA (FRA:MRK) in a research note released on Wednesday. The firm currently has a neutral rating on the healthcare company’s stock.

Several other equities analysts have also recently commented on MRK. Berenberg Bank set a €116.00 ($138.10) target price on Merck KGaA and gave the company a buy rating in a research note on Wednesday, September 13th. Citigroup set a €123.00 ($146.43) target price on Merck KGaA and gave the company a buy rating in a research note on Wednesday, September 13th. Goldman Sachs Group set a €105.00 ($125.00) target price on Merck KGaA and gave the company a neutral rating in a research note on Tuesday, September 19th. Kepler Capital Markets set a €119.00 ($141.67) target price on Merck KGaA and gave the company a buy rating in a research note on Thursday, September 21st. Finally, Morgan Stanley set a €103.00 ($122.62) target price on Merck KGaA and gave the company a neutral rating in a research note on Monday, September 25th. Twelve research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of €107.57 ($128.06).

Merck KGaA (FRA MRK) opened at €91.20 ($108.57) on Wednesday. The firm has a market capitalization of $11,740.00 and a P/E ratio of 21.36. Merck KGaA has a fifty-two week low of €87.33 ($103.96) and a fifty-two week high of €115.00 ($136.90).

ILLEGAL ACTIVITY NOTICE: “Merck KGaA (MRK) Given a €95.00 Price Target at JPMorgan Chase & Co.” was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/merck-kgaa-mrk-given-a-95-00-price-target-at-jpmorgan-chase-co-2/1806473.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with Analyst Ratings Network's FREE daily email newsletter.